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The nuclear receptor corepressors NCoR and SMRT repress gene transcription by recruiting a histone
deacetylase complex.Their roles in PPARγ action have been controversial. Recent evidence, however, suggests
that NCoR and SMRT repress PPARγ-mediated transcriptional activity on specific promoters in the adipocyte.
In addition, by repressing PPARγ action, these corepressors inhibit the ability of adipocyte differentiation to
proceed. A further understanding of corepressor action in the adipocyte will provide insight into the balance
of forces regulating adipogenesis, insulin sensitivity, and Type 2 diabetes mellitus.
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Introduction
The nuclear receptor corepressors were initially identified
as nuclear proteins recruited by the thyroid hormone
receptor (TR) and retinoic acid receptor (RAR) isoforms
to mediate ligand-independent repression. More recently,
they have been shown to modulate the transcriptional
activity of a wide variety of transcription factors.The two
main nuclear receptor corepressors are the nuclear
receptor corepressor protein (NCoR) [Horlein et al., 1995]
and the silencing mediator of retinoid and thyroid hormone
receptors (SMRT) [Chen and Evans, 1995]. Nuclear
hormone receptors (NHRs) generally bind NCoR and
SMRT in the absence of ligand or the presence of
antagonists.These interactions are mediated by CoRNR
box sequences (I/L-x-x-I/V-I) in the interacting domains
of NCoR and SMRT [Hu and Lazar, 1999; Nagy et al.,
1999; Perissi et al., 1999]. Sequences within and outside
these CoRNR box motifs regulate the specificity of
interactions between corepressors and NHRs [Cohen et
al., 2001; Makowski et al., 2003].The binding of ligand
to the NHR results in a conformational change in the
receptor, leading to loss of corepressor binding and
subsequent recruitment of coactivators.
NCoR and SMRT are expressed ubiquitously, and they
function in vitro as corepressors of gene transcription.
However, their exact physiologic roles in distinct tissues
remain relatively undefined, in part due to a lack of
suitable animal models. An NCoR knock-out mouse has
been developed, but NCoR deficiency was found to cause
embryonic lethality [Jepsen et al., 2000].The use of
cortical progenitor cells from NCoR -/- mice showed that
NCoR was important in inhibiting the differentiation of
neural stem cells into astrocytes [Hermanson et al., 2002].
However, the ability of NCoR and SMRT to modulate
differentiation in other tissues remains relatively
unexplored. Recently, we and other groups have found
that NCoR and SMRT play an important role in the
adipocyte.We have focused on the role of these
corepressors in inhibiting adipocyte differentiation, which
appears to occur via repression of peroxisome
proliferator-activated receptor γ (PPARγ) activity.
PPARγ and transcriptional regulation
PPARγ is a member of the nuclear hormone receptor
(NHR) superfamily of transcription, and exists as two
isoforms which differ only in their A/B domains: PPARγ1
and PPARγ2. PPARγ2 is specifically expressed in
adipocytes, and PPARγ response elements are found in
a number of adipocyte-specific genes, including aP2,
phosphoenolpyruvate carboxykinase, acyl-CoA
synthetase, and lipoprotein lipase. Similar to other NHRs,
the PPARγ ligand-binding domain binds multiple classes
of coactivators. PPARγ, particularly the PPARγ2 isoform,
is considered to be the key regulator of adipocyte
differentiation [Rosen et al., 2002]. Recent knock-out
experiments have clarified the roles of PPARγ in vivo.
Knock-out of PPARγ in adipose tissue results in
decreased adipocyte number, and decreased plasma
levels of leptin and adiponectin [He et al., 2003].
Interestingly, these mice exhibit insulin resistance in fat
and liver, but not in muscle, and have normal glucose
tolerance and systemic insulin sensitivity in the basal
state. In contrast, muscle-specific PPARγ -/- mice develop
excess adiposity and systemic insulin resistance [Hevener
et al., 2003; Norris et al., 2003].These data suggest that
PPARγ action is more complex than previously
understood, and that PPARγ plays important roles in
tissues other than the adipocyte. However, the adipocyte
represents a target tissue that is uniquely dependent on
PPARγ action; PPARγ is required for adipogenesis, and
the differentiated adipocyte appears to depend on PPARγ
for its survival [Imai et al., 2004].
PPARγ and nuclear corepressors
There have been limited studies of corepressor
recruitment by PPARγ, and early results were conflicting.
Some studies suggested that PPARγ might not recruit
NCoR or SMRT in the presence of DNA response
elements [Zamir et al., 1997]. Another report suggested
that PPARγ could recruit the corepressor SMRT, but
mainly in the presence of epidermal growth factor (EGF)
[Lavinsky et al., 1998]. Later work showed that PPARγ
was able to recruit nuclear receptor corepressors in cells
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overexpression of NCoR or SMRT repressed
PPARγ-mediated gene transcription in certain cell types
[Krogsdam et al., 2002]. Interestingly, mutant PPARγ
receptors have been found in patients with PPARγ
resistance that release corepressors aberrantly in the
presence of exogenous ligands [Agostini et al., 2004].
Recently, we have shown that NCoR and SMRT
down-regulate PPARγ-mediated transcriptional activity
in 3T3-L1 cells, a fibroblast cell line that retains the ability
to differentiate into adipocytes in the appropriate hormone
milieu [Yu et al., 2005].We used RNA interference to
down-regulate NCoR or SMRT levels in 3T3-L1 cells, and
examined the ability of these cells to undergo
adipogenesis. Interestingly, when stimulated with insulin,
dexamethasone, and isobutylmethylxanthine, these cells
exhibited increased expression of adipocyte-specific
proteins as compared to wild-type cells. Moreover, these
cells exhibited enhanced lipid droplet formation, as
measured by Oil Red O staining.The cells were next
stimulated to differerentiate in a thiazolidinedione
(TZD)-dependent differentiation cocktail.TZDs serve as
ligands for PPARγ, and are used clinically to increase
insulin sensitivity in the treatment of Type 2 diabetes
mellitus [Olefsky, 2000]. Interestingly, cells deficient in
NCoR or SMRT expressed an increased level of
adipocyte-specific proteins when stimulated by TZDs [Yu
et al., 2005].Thus, these data show that NCoR and SMRT
modulate adipogenesis, most likely via their ability to
repress PPARγ action. Moreover, the relative cellular
levels of corepressors and coactivators affect the ability
of PPARγ ligands to induce adipocyte differentiation.
Other groups have also recently examined the ability of
NCoR and SMRT to repress PPARγ transcriptional activity
in 3T3-L1 cells. Guan et al., showed that NCoR and
SMRT are both recruited to PPARγ, but this process is
promoter-specific [Guan et al., 2005].When PPARγ is
recruited to the aP2 promoter, it does not recruit
corepressors; instead PPARγ is bound to coactivators
even in the absence of ligand. In contrast, when PPARγ
is recruited to the glycerol kinase promoter, it recruits
nuclear receptor corepressors and represses gene
transcription in the absence of ligand.While the presence
of ligand does not cause a shift in cofactor recruitment
by PPARγ on the aP2 promoter, ligand results in release
of corepressors and recruitment of coactivators on the
glycerol kinase promoter.These data suggest that
corepressors affect only a fraction of PPARγ-responsive
genes. An area of active research is to identify which
PPARγ-responsive genes are corepressor-dependent
and which are not.
PPARγ, corepressors, and negative
regulation
The standard view of PPARγ-mediated transcription
involves an increase in gene transcription in the presence
of ligands such as TZDs. However, there are many genes
that are negatively regulated by PPARγ ligands. Negative
regulation by PPARγ and other NHRs is poorly
understood. Early work into negative regulation by PPARγ
focused on leptin gene regulation, as it is known that
PPARγ agonists down-regulate leptin mRNA levels [Zhang
et al., 1996]. Interestingly, it was found that the putative
PPARγ response element in the leptin promoter was not
involved in negative regulation and it was hypothesized
that PPARγ functionally antagonized C/EBPα to decrease
transcription in response to TZDs [Hollenberg et al.,
1997]. However, the role of corepressors in this process
was not investigated.
More recently, Pascual et al., investigated the ability of
PPARγ to down-regulate the inducible nitric oxide
synthase (iNOS) gene in macrophages [Pascual et al.,
2005].These authors found that PPARγ ligands cause
SUMOylation of the PPARγ ligand-binding domain.This
process targets PPARγ to NCoR-containing complexes,
and decreases the ability of p50 and p65 complexes to
recruit coactivators.Thus, DNA-associated NCoR may
recruit sumoylated PPARγ to down-regulate gene
transcription in response to TZDs on promoters that do
not contain classical PPARγ / RXR binding sites.
Interestingly, while NCoR was important in negative
regulation of the iNOS promoter, SMRT was ineffective,
suggesting there may be corepressor specificity in terms
of negative regulation by PPARγ [Pascual et al., 2005].
While this work was performed in macrophages, these
results shed insight into potential ways that corepressors
might also influence PPARγ –mediated negative
regulation in adipocytes.
The paradox of the PPARγ heterozygous
knock-out
TZDs serve as high affinity ligands for PPARγ receptors,
and their effects on insulin sensitivity are thought to be
dependent on this activity. Since PPARγ -/- mice die in
utero, PPARγ +/- heterozygotes have been used to study
the effects of PPARγ on insulin sensitivity. It was
hypothesized that a reduction in PPARγ number would
reduce insulin sensitivity. Paradoxically, PPARγ +/- mice
have enhanced insulin sensitivity [Miles et al., 2000]. One
potential explanation is that PPARγ recruits corepressors
as well as coactivators.TZDs might increase insulin
sensitivity via the recruitment of coactivators, whereas a
decrease in PPARγ number would increase insulin
sensitivity via a decrease in corepressor action [Miles et
al., 2000].
As noted above, knock-out of PPARγ in adipose tissue
results in decreased adipocyte number [He et al., 2003].
Interestingly, adipocyte-specific PPARγ knock-out mice
exhibit normal systemic insulin sensitivity in the basal
state, but are susceptible to insulin resistance induced
by high-fat feeding [He et al., 2003]. In contrast,
muscle-specific PPARγ -/- mice exhibit systemic insulin
resistance even in the basal state [Hevener et al., 2003;
Norris et al., 2003].Thus, the in vivo function of PPARγ
is complex, and further work will clarify the role of PPARγ
in distinct tissues, including its relationship with NCoR
and SMRT.
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Increasing evidence suggests that the corepressors NCoR
and SMRT play an important role in adipocyte
differentiation and PPARγ transcriptional activity. It
appears that only a subset of PPARγ-responsive genes
is corepressor-dependent (see Figure 1). In addition,
corepressors may also mediate negative regulation by
PPARγ. Future work will delineate the roles of NCoR and
SMRT in the adipocyte and determine which genes are
regulated by corepressor activity. Currently, modulation
of PPARγ transcriptional activity by TZDs is used as a
mainstay of treatment for Type 2 diabetes mellitus
[Olefsky, 2000]. However, TZDs are associated with side
effects such as weight gain and edema.We hypothesize
that alterations in corepressor activity might also allow
for the modulation of PPARγ activity in the adipocyte and
may represent an alternative or complementary
therapeutic approach to the TZD class of medication.
Figure 1. Corepressors modulate PPARγ activity via distinct
mechanisms Nuclear receptor corepressors (CoRs) are recruited to
PPARγ on a subset of PPARγ-responsive positively-regulated genes (a).
On these genes, corepressors repress PPARγ activity in the absence of
ligand.The presence of ligands such as TZDs causes release of
corepressors and recruitment of coactivators (CoAs). On other genes (b),
PPARγ does not recruit corepressors, and these genes are transcriptionally
active even in the absence of ligand. Still other genes are negatively
regulated by PPARγ ligands (c). On these genes PPARγ may be recruited
to the promoter by protein-protein interactions.
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